Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol dosing regimens in persistent asthma
NL-OMON34929Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indacaterol in asthma (4 arms), sponsored by Novartis. Primary endpoint: Trough FEV1 after 2 weeks of treatment. Started Mar 2010; status: active, not recruiting.
02
Drugs
indacaterol
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON34929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34929.